Photo by timothyeberly from unsplash
The benefits of adding anti‐EGFR therapy to conventional chemoradiotherapy (CRT) for nasopharyngeal carcinoma (NPC) remain uncertain, possibly because only a subgroup of patients show better outcome. To address this issue,… Click to show full abstract
The benefits of adding anti‐EGFR therapy to conventional chemoradiotherapy (CRT) for nasopharyngeal carcinoma (NPC) remain uncertain, possibly because only a subgroup of patients show better outcome. To address this issue, we compared the efficacy of CRT plus cetuximab (CTX) or nimotuzumab (NTZ) to CRT alone for stage II‐IVb NPC and examined possible prognostic indicators, including tumour EGFR and VEGR expression levels.
Keywords:
stage ivb;
chemoradiotherapy;
anti egfr;
alone stage;
nasopharyngeal carcinoma
Journal Title: Clinical Otolaryngology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Otolaryngology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!